RAD14 Antibody

Shipped with Ice Packs
In Stock

Product Specs

Buffer
Preservative: 0.03% Proclin 300
Composition: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Form
Liquid
Lead Time
Made-to-order (14-16 weeks)
Synonyms
RAD14 antibody; CAALFM_C702020WA antibody; CaJ7.0232 antibody; CaO19.13870 antibody; CaO19.6517 antibody; DNA repair protein RAD14 antibody
Target Names
RAD14
Uniprot No.

Target Background

Function
RAD14 Antibody is involved in DNA excision repair.
Database Links
Protein Families
XPA family
Subcellular Location
Nucleus.

Q&A

What is RAD14 and what role does it play in DNA repair mechanisms?

RAD14 is a DNA damage recognition protein that functions in yeast Nucleotide Excision Repair (NER). It serves as an early factor in the NER cascade, recognizing and verifying DNA damage sites before downstream repair factors are recruited. RAD14 is believed to function prior to the Rad1-Rad10 endonuclease complex, which acts downstream by incising DNA 5' to the site of damage . The human homolog of yeast RAD14 is XPA, which performs similar functions in human cells. Understanding RAD14's role is critical for investigating the molecular basis of NER and its implications in various pathological conditions, particularly skin cancer development .

What visualization techniques are effective for studying RAD14 localization?

Fluorescence microscopy using fusion proteins is particularly effective for studying RAD14 localization. Researchers have successfully created strains where RAD14 is fused to Cyan Fluorescent Protein (RAD14-CFP) to observe its recruitment to DNA damage sites in live cells . When using this approach:

  • CFP fluorescence allows visualization of RAD14 as nuclear-localized fluorescent foci in response to UV irradiation

  • Peak induction of RAD14-CFP foci typically occurs approximately 15 minutes post-irradiation

  • Time-lapse experiments indicate that RAD14-CFP foci are transient, generally persisting less than 6 minutes

  • Z-stack imaging (11 images with 0.3 μm focal plane offset) ensures capturing the entire cell thickness

This methodology enables researchers to track the temporal dynamics of RAD14 recruitment to damage sites with high precision.

What model organisms and cell types are suitable for RAD14 antibody applications?

Based on available research, several model systems have been validated for RAD14 studies:

Model SystemApplicationsNotes
Saccharomyces cerevisiaeGenetic studies, fluorescence microscopyMost common model for RAD14 studies
Human cell linesImmunofluorescence, Western blotUsed for studies with XPA (human homolog)
Mouse modelsImmunohistochemistryFor tissue-specific expression studies
Rat systemsWestern blot, immunoprecipitationLess common but validated

When designing experiments with RAD14 antibodies, researchers should consider genetic background effects. For instance, the W303-1A background in S. cerevisiae has been extensively used for RAD14-CFP expression studies . Verification of antibody specificity within your chosen model system is essential, as cross-reactivity can occur between related DNA repair proteins.

How should UV induction experiments be designed to study RAD14 recruitment?

When designing UV induction experiments to study RAD14 recruitment, researchers should follow these methodological steps:

  • Culture preparation: Start and propagate cultures in Synthetic Complete medium supplemented with 200 μg/mL Adenine (SC + ade) at 23°C

  • Pre-irradiation setup: Freshly dilute overnight cultures (to 0.1 OD600) and incubate for 3 hours prior to UV treatment

  • UV exposure protocol: Transfer cells to sterile 110 × 15 mm Petri dishes and expose to UV-C light (20 J/m²)

  • Post-irradiation handling: Transfer cells to fresh culture tubes, wrap in aluminum foil (to prevent photoreactivation), and incubate for the desired time period before microscopy

For time-lapse experiments specifically, cells should be UV irradiated as droplets directly on microscope slides and quickly mounted with 2% low-melting agarose in SC + ade medium . This approach allows for continuous observation of RAD14 dynamics at damage sites over time.

What are the critical considerations for validating RAD14 antibody specificity?

Validation of RAD14 antibody specificity requires multiple complementary approaches:

  • Genetic controls: Compare antibody response in wild-type versus rad14Δ mutant strains

  • Protein size verification: Confirm detection of the correct molecular weight protein (calculated molecular weight ~33 kDa, though observed molecular weight may differ due to post-translational modifications)

  • Cross-reactivity testing: Test against related proteins, particularly other XP family proteins

  • Multiple application validation: Verify specificity across different applications (e.g., Western blot, immunofluorescence, ChIP)

  • Peptide competition assays: Confirm binding specificity using blocking peptides corresponding to the immunogen sequence

Each validation step should be thoroughly documented with appropriate controls to ensure reliable experimental outcomes.

How can researchers effectively compare RAD14 and Rad10 recruitment dynamics?

To effectively compare RAD14 and Rad10 recruitment dynamics, researchers should:

  • Generate dual-labeled strains expressing both RAD14-CFP and Rad10-YFP fusion proteins

  • Employ time-resolved microscopy following UV irradiation, with image acquisition at multiple timepoints (e.g., 15 min, 30 min, 1 hr, 2 hr post-UV)

  • Quantify the percentage of cells showing foci formation for each protein at each timepoint

  • Analyze the temporal relationship between the appearance of RAD14-CFP and Rad10-YFP foci

Research has established that:

  • RAD14-CFP foci form earlier, with peak induction at approximately 15 minutes post-irradiation

  • Rad10-YFP foci formation peaks approximately 2 hours post-irradiation

  • RAD14-CFP foci are transient (typically persisting less than 6 minutes)

  • Rad10-YFP recruitment is dependent on functional RAD14, as demonstrated in rad14Δ mutants

These observations support a stepwise model of NER protein assembly where RAD14 acts as an early factor required for the subsequent recruitment of the Rad1-Rad10 complex.

How can RAD14 antibodies be used to investigate protein-protein interactions within the NER complex?

RAD14 antibodies can be instrumental in elucidating protein-protein interactions within the NER complex through several methodological approaches:

  • Co-immunoprecipitation (Co-IP): Use RAD14 antibodies to pull down RAD14 and associated proteins, followed by Western blot analysis to identify interacting partners. This has revealed direct physical interactions between RAD14 and the Rad1-Rad10 complex .

  • Proximity ligation assay (PLA): Employ RAD14 antibodies in combination with antibodies against other NER factors to visualize protein-protein interactions in situ with single-molecule resolution.

  • ChIP-sequential immunoprecipitation (ChIP-seq IP): First immunoprecipitate with RAD14 antibodies, then with antibodies against other NER factors to identify DNA regions where multiple repair factors co-localize.

  • Fluorescence resonance energy transfer (FRET): Combine RAD14 antibodies labeled with donor fluorophores and antibodies against potential interacting partners labeled with acceptor fluorophores to detect nanometer-scale proximity in fixed cells.

When investigating these interactions, it's critical to control for non-specific binding and to confirm results with multiple methodologies, as transient interactions may be difficult to capture with any single technique.

What are the key methodological differences between studying RAD14 in yeast versus human cell systems?

The methodological approaches for studying RAD14 (yeast) versus XPA (human homolog) differ significantly:

ParameterYeast SystemsHuman Cell Systems
Genetic manipulationHighly efficient homologous recombination; easy gene tagging and knockoutCRISPR/Cas9 required for precise editing; lower efficiency
Expression systemsChromosomal integration preferred; native promoter controlOften relies on plasmid-based overexpression
Visualization methodsDirect fluorescent protein tagging (e.g., RAD14-CFP)Primarily antibody-based immunofluorescence
UV sensitivityGenerally more resistant than human cells; requires higher UV dosesMore sensitive; lower UV doses sufficient
Experimental timelineRapid growth (2-3 hour doubling time)Slower experiments due to longer doubling time (24+ hours)
Protein sizeRAD14: ~33 kDa (calculated); observed at ~72 kDa XPA: ~31 kDa; varies with post-translational modifications

When translating findings between systems, researchers should account for these differences and validate key observations in both systems whenever possible.

How can conflicting data on RAD14 recruitment timing be reconciled?

Conflicting data on RAD14 recruitment timing can stem from multiple experimental variables. To reconcile such discrepancies, researchers should:

  • Standardize UV damage protocols: Different UV wavelengths, doses, and delivery methods can significantly affect recruitment kinetics

    • UV-C (254 nm) produces primarily CPD and 6-4PP lesions

    • Filtered UV sources may produce different damage profiles

  • Account for cell cycle effects: RAD14 recruitment efficiency varies across the cell cycle

    • Synchronize cell populations or use cell cycle markers to stratify results

    • Compare recruitment in G1 versus S and G2 phases

  • Consider the detection method sensitivity:

    • Fluorescent protein fusions may have different detection thresholds than antibody-based methods

    • Image acquisition parameters significantly impact detection of transient foci

  • Analyze protein expression levels:

    • Overexpression systems may show altered kinetics compared to endogenous expression

    • Single-cell analysis techniques may reveal population heterogeneity masked in bulk studies

The observed transient nature of RAD14-CFP foci (persisting less than 6 minutes) may explain why some studies miss this recruitment event entirely, particularly if sampling timepoints are too widely spaced.

What are the optimal storage and handling conditions for RAD14 antibodies?

Proper storage and handling of RAD14 antibodies is crucial for maintaining their specificity and sensitivity:

  • Long-term storage: Store at -20°C for up to one year in aliquots to minimize freeze-thaw cycles

  • Short-term storage: For frequent use, store at 4°C for up to one month

  • Buffer composition: PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide provides optimal stability

  • Freeze-thaw cycles: Avoid repeated freeze-thaw cycles as they significantly reduce antibody activity

  • Working dilutions: Prepare fresh working dilutions for each experiment rather than storing diluted antibody

When troubleshooting reduced antibody performance, first consider storage conditions and the number of freeze-thaw cycles the antibody has undergone, as these are common sources of sensitivity loss.

What are the recommended dilutions and conditions for RAD14 antibody applications?

While specific recommendations for RAD14 antibodies were not provided in the search results, general guidelines for polyclonal antibodies similar to RAD14 antibodies include:

ApplicationRecommended Dilution RangeOptimization Notes
Western Blot (WB)1:500 - 1:2000Start with 1:1000; adjust based on signal intensity
Immunohistochemistry (IHC)1:100 - 1:300Lower dilutions for fixed tissue samples
Immunocytochemistry (ICC)1:200 - 1:1000Cell type may affect optimal dilution
Immunofluorescence (IF)1:200 - 1:1000Signal amplification may be needed for low abundance proteins
ELISA1:20000Higher dilutions typically work well for ELISA

These recommendations provide starting points for assay optimization. The actual working concentration varies and should be determined empirically for each specific application and experimental system .

How can researchers troubleshoot non-specific binding when using RAD14 antibodies?

When encountering non-specific binding with RAD14 antibodies, researchers should implement these troubleshooting strategies:

  • Blocking optimization:

    • Increase blocking time (1-2 hours at room temperature or overnight at 4°C)

    • Test different blocking agents (BSA, normal serum, casein, commercial blockers)

    • Use the blocking agent in antibody dilution buffers

  • Antibody concentration:

    • Titrate the primary antibody to find the optimal concentration that maximizes specific signal while minimizing background

    • Consider using higher dilutions with longer incubation times

  • Washing protocol adjustments:

    • Increase the number of washes (5-6 washes of 5-10 minutes each)

    • Add low concentrations of detergent (0.05-0.1% Tween-20) to wash buffers

    • Consider higher salt concentrations in wash buffers

  • Pre-adsorption:

    • Pre-adsorb the antibody with cell/tissue lysate from RAD14-knockout samples

    • Use commercial pre-adsorption kits to remove cross-reactive antibodies

  • Compare results with alternative RAD14 antibodies raised against different epitopes to confirm specificity of observed signals.

How might RAD14 antibodies contribute to understanding the role of RAD14 in cancer development?

RAD14 antibodies could significantly advance our understanding of RAD14's role in cancer development through several research avenues:

  • Diagnostic biomarker development:

    • Compare RAD14 expression and localization patterns in normal versus tumor tissues

    • Correlate RAD14 abnormalities with DNA repair deficiencies and genomic instability profiles

    • Develop immunohistochemistry panels including RAD14 for cancer classification

  • Mechanistic studies:

    • Investigate RAD14 interactions with other DNA repair pathways beyond NER

    • Map RAD14 recruitment to damage sites in the context of chromatin modifications associated with cancer

    • Examine how RAD14 function is affected by cancer-associated mutations

  • Therapeutic response prediction:

    • Assess RAD14 status as a potential predictor of response to DNA-damaging chemotherapies

    • Investigate whether RAD14 deficiencies create synthetic lethal opportunities with emerging therapeutics

    • Explore RAD14 as a potential target for cancer treatments

Knowledge that RAD14 is involved in the molecular recognition of DNA damage suggests its dysfunction could contribute to the genomic instability that characterizes many cancers . Understanding these connections may provide insights into both cancer development and potential therapeutic vulnerabilities.

What emerging technologies could enhance the study of RAD14 dynamics in live cells?

Several emerging technologies could revolutionize the study of RAD14 dynamics in live cells:

  • Super-resolution microscopy techniques:

    • Stimulated emission depletion (STED) microscopy

    • Photoactivated localization microscopy (PALM)

    • Stochastic optical reconstruction microscopy (STORM)

    These approaches could resolve RAD14 localization at the nanometer scale, potentially revealing previously undetectable substructures within repair foci.

  • Optogenetic tools:

    • Photocaged RAD14 variants that can be activated at specific cellular locations

    • Light-inducible protein-protein interaction systems to control RAD14 recruitment

    • Optogenetic damage induction systems for precise spatiotemporal control

  • CRISPR-based technologies:

    • CRISPR-based live-cell DNA labeling to visualize damage sites simultaneously with RAD14

    • CRISPRa/CRISPRi for temporally controlled modulation of RAD14 expression

    • Prime editing approaches for introducing specific mutations in RAD14

  • Advanced fluorescent biosensors:

    • FRET-based sensors to detect RAD14 conformational changes upon DNA binding

    • Split fluorescent protein complementation to visualize RAD14 interactions in real-time

    • Fluorescent timers to track the age of RAD14 repair complexes

These technologies could help resolve the transient nature of RAD14 foci (reported to persist less than 6 minutes) with greater precision and provide deeper insights into the molecular triggers driving NER progression.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.